European Journal of Clinical Pharmacology

, Volume 23, Issue 2, pp 111–121 | Cite as

Individualized aminophylline therapy in patients with obstructive airway disease: Oral dosage prediction from an intravenous test dose

  • Y. Horai
  • T. Ishizaki
  • T. Sasaki
  • M. Watanabe
  • J. Kabe
Originals

Summary

Theophylline disposition after an intravenous test dose of aminophylline was determined in 83 subjects: 7 patients with and 58 without congestive heart failure (CHF), and 18 healthy controls. Based on the pharmacokinetics of theophylline in the individual, the oral dosage of aminophylline was scheduled to attain steady-state trough theophylline concentrations (Cpred) near the therapeutic margin. Significant differences in theophylline clearance with a relatively constant volume of distribution were observed between various groups divided by age, smoking habit and CHF; the significantly different (p<0.001) mean clearance values were: 0.042±0.0161/h/kg (mean ± SD) in patients without CHF (n=58) as opposed to 0.016±0.001 l/h/kg in patients with CHF(n=7), 0.038±0.013 l/h/kg in non-smokers (n=59) versus 0.054±0.015 l/h/kg in smoking subjects (n=17), and 0.030±0.010 l/h/kg in elderly (>60 years) non-smoking patients (n=7) versus 0.057±0.017 l/h/kg in smoking patients (n=5) aged 40 to 59 years. No gender-related difference was detected in theophylline disposition. For all subjects together (n=83), there was no significant correlation between age and clearance (r=-0.111, p>0.1). The multivariate analysis indicated that the overall variability in theophylline clearance was affected first by the smoking habit (t=4.960; p<0.001) and second by CHF (t=-3.052; p<0.001), but not by age (t=1.140) or by sex (t=0.069). 78% of the patients who did not have CHF required a daily dose of aminophylline of 600 to 900 mg, whereas a dose of 300 to 450 mg was the rule in patients with CHF. The measured steady-state minimum concentration (Cmeas) ranged from 5.4 to 14.6 µg/ml (9.0±2.2 µg/ml: mean ± SD) which was in good agreement with the Cpred (5.6 to 13.6, 9.0±1.6 µg/ml) in all patients (n=60) who received the oral dose of aminophylline calculated from the test dose. The overall prediction error was -0.08±1.83 µg/ml (−1.42±19.90%); only 3 of 60 measurements were found to be outside±2 SD. It is concluded that using a test dose to individualize aminophylline therapy is likely to remain the most reliable means to assure the maximum therapeutic benefit in patients with airway obstruction.

Key words

aminophylline asthma individual aminophylline dose theophylline disposition intravenous test dose oral dosage prediction 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jenne WJ, Wyze E, Rood FS, MacDonald FM (1972) Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline. Clin Pharmacol Ther 13:349–360Google Scholar
  2. 2.
    Hendeles L, Bighley L, Richardson RH, Hepler CD, Carmichael J (1977) Frequent toxicity from IV aminophylline infusions in critically ill patients. Drug Intell Clin Pharm 11:12–18Google Scholar
  3. 3.
    Jusko WJ, Koup JR, Vance JW, Schentag JJ, Kuritzky P (1977) Intravenous theophylline therapy: Nomogram guidelines. Ann Intern Med 86:400–404Google Scholar
  4. 4.
    Ogilvie RI (1978) Clinical pharmacokinetics of theophylline. Clin Pharmacokinet 3:267–293Google Scholar
  5. 5.
    Hendeles L, Weinberger M, Johnson G (1978) Monitoring serum theophylline levels. Clin Pharmacokinet 3:294–312Google Scholar
  6. 6.
    Mitenko PA, Ogilvie RI (1973) Rational intravenous doses of theophylline. N Engl J Med 289:600–603Google Scholar
  7. 7.
    Piafsky KM, Ogilvie RI (1975) Dosage of theophylline in bronchial asthma. N Engl J Med 292:1218–1222Google Scholar
  8. 8.
    Zwillich CW, Sutton FD, Neff TA, Cohn WM, Matthay RA, Weinberger MM (1975) Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann Intern Med 82:784–787Google Scholar
  9. 9.
    Koup JR, Schentag JJ, Vance JW, Kuritzky PM, Pyszczynski DR, Jusko WJ (1976) System for clinical pharmacokinetic monitoring of theophylline therapy. Am J Hosp Pharm 33:949–956Google Scholar
  10. 10.
    Powell JR, Thiercelin J-F, Vozeh S, Sansom L, Riegelman S (1977) The influence of cigarette smoking and sex on theophylline disposition. Am Rev Respir Dis 116:17–23Google Scholar
  11. 11.
    Hendeles L, Weinberger M, Bighley L (1978) Disposition of theophylline after a single intravenous infusion of aminophylline. Am Rev Respir Dis 118:97–103Google Scholar
  12. 12.
    Powell JR, Vozeh S, Hopewell P, Costello J, Sheiner LB, Riegelman S (1978) Theophylline disposition in actuely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia. Am Rev Respir Dis 118:229–238Google Scholar
  13. 13.
    Slotfeldt ML, Johnson CE, Grambau G, Weg JG (1979) Reliability of theophylline clearance in determining chronic oral dosage regimens. Am J Hosp Pharm 37:66–68Google Scholar
  14. 14.
    Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW (1979) Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci 68:1358–1366Google Scholar
  15. 15.
    Gal P, Jusko WJ, Yurchak AM, Franklin BA (1978) Theophylline disposition in obesity. Clin Pharmacol Ther 23:438–450Google Scholar
  16. 16.
    American Thoracic Society (1962) Definition and classification of chronic bronchitis, asthma, and pulmonary emphysema. Am Rev Respir Dis 85:762–768Google Scholar
  17. 17.
    McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: The Framingham Study. N Engl J Med 285:1441–1446Google Scholar
  18. 18.
    Nielsen-Kudsk F, Magnussen I, Jakobsen P (1978) Pharmacokinetics of theophylline in ten elderly patients. Acta Pharmacol Toxicol 42:226–234Google Scholar
  19. 19.
    Adams RF, Vandemark FL, Schmidt GJ (1976) More sensitive high-pressure liquid-chromatographic determination of theophylline in serum. Clin Chem 22:1903–1906Google Scholar
  20. 20.
    Ishizaki T, Watanabe M, Morishita N (1979) The effect of assay methods on plasma levels and pharmacokinetics of theophylline: HPLC and EIA. Br J Clin Pharmacol 7:333–341Google Scholar
  21. 21.
    Chrzanowski FA, Niebergall PJ, Mayock RJ, Taubin JM, Sugita ET (1977) Kinetics of intravenous theophylline. Clin Pharmacol Ther 22:188–195Google Scholar
  22. 22.
    Dvorchik BH, Vesell ES (1978) Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs. Clin Pharmacol Ther 23:617–623Google Scholar
  23. 23.
    Pancorbo S, Sawchuk RJ, Dashe C, Schallock M (1979) Use of a pharmacokinetic model for individualizing intravenous doses of aminophylline. Eur J Clin Pharmacol 16:251–254Google Scholar
  24. 24.
    Sawchuk RJ, Zaske DE (1976) Pharmacokinetics of dosing regimens which utilize multiple intravenous infusion: Gentamicin in burn patients. J Pharmacokinet Biopharm 4:183–195Google Scholar
  25. 25.
    Wagner JG (1975) Fundamentals of Clinical Pharmacokinetics. 1st edn., Drug Intelligence Publications Hamilton, ILGoogle Scholar
  26. 26.
    Hendeles L, Weinberger M, Bighley L (1977) Absolute bioavailability of oral theophylline. Am J Hosp Pharm 34:525–527Google Scholar
  27. 27.
    Fixley M, Shen DD, Azarnoff DL (1977) Theophylline bioavailability. A comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis 115:955–962Google Scholar
  28. 28.
    Draper NR, Smith H (1966) Applied regression analysis. John Wiley & Sons, New York London SydneyGoogle Scholar
  29. 29.
    Weinberger M, Ginchansky E (1976) Theophyllinization of the child with chronic asthma. In: Gouveia WA, Tognoni G, Van der Kleijin E (eds) Clinical Pharmacy and Clinical Pharmacology. Elsevier/North-Holland, Amsterdam, 319–328Google Scholar
  30. 30.
    Jenne JW, Nagasawa HT, Thompson RD (1976) Relationship of urinary metabolites of theophylline to serum theophylline levels. Clin Pharmacol Ther 19:375–381Google Scholar
  31. 31.
    Monks TJ, Caldwell J, Smith RL (1979) Influence of methylxanthine-containing foods on theophylline metabolism and kinetics. Clin Pharmacol Ther 26:513–524Google Scholar
  32. 32.
    Grygiel JJ, Wing LMH, Farkas J, Birkett DJ (1979) Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther 26:660–667Google Scholar
  33. 33.
    Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI (1977) Theophylline kinetics in acute pulmonary edema. Clin Pharmacol Ther 21:310–316Google Scholar
  34. 34.
    Vicuna N, McNay JL, Ludden TM, Schwertner H (1979) Impaired theophylline clearance in patients with cor pulmonale. Br J Clin Pharmacol 7:33–37Google Scholar
  35. 35.
    Hendeles L, Vaughan L, Weinberger M, Smith G (1980) Influence of gender on theophylline dosage requirements in children with chronic asthma. Drug Intell Clin Pharm 15:338–340Google Scholar
  36. 36.
    Vozeh S, Kewitz G, Wenk M, Follath F (1980) Rapid prediction of steady-state serum theophylline concentration in patients treated with intravenous aminophylline. Eur J Clin Pharmacol 18:473–477Google Scholar
  37. 37.
    Cooper TB, Simpson GM (1978) Prediction of individual dosage of nortriptyline. Am J Psychiatry 135:333–335Google Scholar
  38. 38.
    Brunswick DJ, Amsterdam JD, Mendels J, Stern SL (1979) Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data. Clin Pharmacol Ther 25:605–610Google Scholar
  39. 39.
    Dawling S, Crome R, Braithwaite A, Lewis RR (1980) Notriptyline therapy in elderly patients: Dosage prediction after single dose pharmacokinetic study. Eur J Clin Pharmacol 18:147–150Google Scholar
  40. 40.
    Resar RK, Walson PD, Fritz WL, Perry DF, Barbee RA (1979) Kinetics of theophylline. Variability and effect of arterial pH in chronic obstructive lung disease. Chest 76:11–16Google Scholar
  41. 41.
    Vozeh S, Powell JR, Riegelman S, Costello JF, Sheiner LB, Hopewell PC (1978) Changes in theophylline clearance during acute illness. J Am Med Assoc 240:1882–1884Google Scholar
  42. 42.
    Chang KC, Bell TD, Lauer BA, Chai H (1978) Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1:1132–1133Google Scholar
  43. 43.
    Weinberger M, Ginchansky E (1977) Dose-dependent kinetics of theophylline disposition in asthmatic children. J Pediatr 91:820–824Google Scholar
  44. 44.
    Sarrazin E, Hendeles L, Weinberger M, Muir K, Riegelman S (1980) Dose-dependent kinetics for theophylline: Observations among ambulatory asthmatic children. J Pediatr 97:825–828Google Scholar
  45. 45.
    Arnold LA, Spurbeck GH, Shelver WH, Henderson WM (1979) Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm 36:1059–1062Google Scholar
  46. 46.
    Welling PG, Lyons LL, Craig WA, Trochta GA (1975) Influence of diet and fluid on bioavailability of theophylline. Clin Pharmacol Ther 17:475–480Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • Y. Horai
    • 1
    • 2
  • T. Ishizaki
    • 1
    • 2
  • T. Sasaki
    • 1
    • 2
  • M. Watanabe
    • 1
    • 2
  • J. Kabe
    • 1
    • 2
  1. 1.Division of Clinical PharmacologyClinical Research InstituteTokyoJapan
  2. 2.Division of Respiratory Disease, Department of MedicineNational Medical CenterTokyoJapan

Personalised recommendations